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Prostate cancer has just become the most commonly registered
cancer of males in the United Kingdom, overtaking lung cancer in
the registration sweepstakes, and is the second most common
cause of male cancer deaths. Deaths have trebled over the last 30
years, plateauing in the mid-1990s but recently increasing again
(Office for National Statistics, 2001).
Locally advanced and metastatic prostate cancer is treated with
antiandrogens and the importance of the side effects of treat-
ment have become more significant as the incidence of this
malignancy has increased. These side effects from treatment
range from hot flushes, impotence, breast tenderness and
enlargement, and diarrhoea to the physically more significant side
effects, which include anaemia, loss of muscle bulk, neurological
dysfunction, and osteoporosis. All of these side effects occur as a
consequence of androgen deficiency. We would argue that the
development of osteoporosis is the most important of these side
effects and that we need to be more proactive in our management
of this condition.
The risk of osteoporotic fracture as a consequence of
antiandrogen therapy has been described in five studies. In a
group of 235 patients with prostate cancer, the cumulative risk of
fracture at 7 years was 28% in 59 castrated men and 1% in 176 men
treated with a GnRH agonist (Daniell, 1997). In a second study, 9%
of 224 men treated with an LHRH agonist had a fracture over a
median follow-up of 22 months; seven of these men had fractures
resulting from osteoporosis, eight men from trauma, and five of
mixed aetiology (Townsend et al, 1997). In a third study of 218
men, 6% had an osteoporotic fracture during 6 or more months
treatment with anti-androgen therapy (Hatano et al, 2000); in a
fourth study, 20% of 181 men treated for 10 years had osteoporotic
fractures (Oefelein et al, 2001). Fracture rates were described in
429 men with prostate cancer treated by bilateral orchiectomy.
There were 267 fractures in 161 men. The increased risk due to
osteoporosis was reported as a standard incidence ratio of 3.50
(95% CI 2.71–4.43) (Melton et al, 2003).
The increased risk of fracture in these men is due to accelerated
loss of bone mineral density and is of early onset. Decreases of
6.6% at the lumbar spine have been seen only after 6 months of
treatment and decreases of 6% at the femoral neck after 18 months
treatment (Diamond et al, 1998). In a French study, changes in
bone mineral density were evaluated in 12 men with prostate
cancer treated with triptorelin. Men with metastases, radiographic
evidence of osteoporosis, or pre-existing conditions associated
with accelerated bone loss were excluded from the study. Bone
mineral density was measured at baseline, 6, 12, and 18 months.
Bone mineral density of the lumbar spine and femoral neck
tended to decrease from month 6, but only reached statistical
significance at 18 months (Maillefert et al, 1999). In an American
study, changes in bone mineral density were evaluated in 26 men
with prostate cancer treated by orchiectomy or with GnRH
agonists. Bone mineral density was measured at 6–42 months.
The average bone mineral density of the hip decreased by 7.6%
during the first orchiectomy, and similar rates of bone loss were
observed among men treated with the GnRH agonists. Rates of
bone loss were highest among inactive and obese men (Daniell
et al, 2000).
These significant changes in bone mineralisation can be
prevented. This has been shown by a recent study, where patients
with locally advanced or recurrent nonmetastatic prostate cancer
receiving leuprolide were randomised to receive pamidronate
given every 3 months for 1 year. In the bisphosphonate group bone
mineral density did not decrease, while in the control group
mineralisation decreased by 3.3% in the lumbar spine and 2.1% at
the hip (Smith et al, 2001). This benefit has been confirmed in an
Australian study (Diamond et al, 2001) and in an American study
where 106 patients were randomised to receive 3 monthly
Zoledronic acid for 1 year (Smith et al, 2003a). An alternative
approach might be to use an antiandrogen without adverse effects
on bone. Bicalutamide monotherapy increases serum levels of
testosterone and oestradiol, indicating that osteoporosis might be
less likely than with other antiandrogens. Urinary markers of bone
turnover in bicalutamide-treated patients were higher than in
gonadotrophin-releasing hormones against treated patients (Smith
et al, 2003b). However, there have been no studies that have
assessed bone mineralisation densities in patients treated with
bicalutamide as compared with other antiandrogens. In clinical
practice, bicalutamide is frequently given with a gonadotrophin-
releasing hormone agonist and the effects of this combination on
bone turnover are not known.
So, it would appear that there is a clear way to limit the effects of
antiandrogen treatment on bone and that is by giving bispho-
sphonate treatment prophylactically. What is unclear is the
bisphosphonate dosage regimen to be used. There are new, highly
effective third-generation bisphosphonates curr-ently available
and it may be that a limited trial is required to investigate this
issue of dosage and frequency of bisphosphonate administration. *Correspondence: Professor J Waxman; E-mail: j.waxman@imperial.ac.uk
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